A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
Novartis
Novartis
Novartis
Mayo Clinic
Incyte Corporation
Stanford University
BerGenBio ASA
Sumitomo Pharma America, Inc.
Celgene
INSYS Therapeutics Inc
National Cancer Institute (NCI)